{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:19:09Z","timestamp":1784265549985,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:00:00Z","timestamp":1550102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["171101003"],"award-info":[{"award-number":["171101003"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bronovo Research Foundation","award":["001"],"award-info":[{"award-number":["001"]}]},{"name":"Franje1 Foundation","award":["001"],"award-info":[{"award-number":["001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3789-6","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T09:04:33Z","timestamp":1550135073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1486-3045","authenticated-orcid":false,"given":"Janneke Evelyne","family":"Stalenhoef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"van Nieuwkoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius Cameron","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willize Elizabeth","family":"van der Starre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanny J. K.","family":"van der Reijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie Manon","family":"Delfos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane Madeleine Sophie","family":"Leyten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christiaan","family":"Ablij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes (Jan) Willem","family":"van \u2018t Wout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap Tamino","family":"van Dissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,14]]},"reference":[{"key":"3789_CR1","doi-asserted-by":"crossref","unstructured":"van Nieuwkoop C, van der Starre WE, Stalenhoef JE, van Aartrijk AM, van der Reijden TJ, Vollaard AM, Delfos NM, van 't Wout JW, Blom JW, Spelt IC et al: Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med 2017, 15(1):70.","DOI":"10.1186\/s12916-017-0835-3"},{"issue":"3","key":"3789_CR2","doi-asserted-by":"publisher","first-page":"R96","DOI":"10.1186\/cc4955","volume":"10","author":"M Christ-Crain","year":"2006","unstructured":"Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, Tamm M, Struck J, Bergmann A, Muller B. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care. 2006;10(3):R96.","journal-title":"Crit Care"},{"key":"3789_CR3","doi-asserted-by":"crossref","unstructured":"Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;9 CD007498.","DOI":"10.1002\/14651858.CD007498.pub2"},{"issue":"9713","key":"3789_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","volume":"375","author":"L Bouadma","year":"2010","unstructured":"Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463\u201374.","journal-title":"Lancet"},{"issue":"1","key":"3789_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13054-018-2001-5","volume":"22","author":"G Elke","year":"2018","unstructured":"Elke G, Bloos F, Wilson DC, Brunkhorst FM, Briegel J, Reinhart K, Loeffler M, Kluge S, Nierhaus A, Jaschinski U, et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial. Crit Care. 2018;22(1):79.","journal-title":"Crit Care"},{"issue":"10","key":"3789_CR6","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/1469-0691.12645","volume":"20","author":"WE Starre van der","year":"2014","unstructured":"van der Starre WE, Zunder SM, Vollaard AM, van NC, Stalenhoef JE, Delfos NM, van't Wout JW, Spelt IC, Blom JW, Leyten EM, et al. Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting outcome of febrile urinary tract infection. Clin Microbiol Infect. 2014;20(10):1048\u201354.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"3789_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13613-017-0238-9","volume":"7","author":"D Andaluz-Ojeda","year":"2017","unstructured":"Andaluz-Ojeda D, Nguyen HB, Meunier-Beillard N, Cicuendez R, Quenot JP, Calvo D, Dargent A, Zarca E, Andres C, Nogales L, et al. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity. Ann Intensive Care. 2017;7(1):15.","journal-title":"Ann Intensive Care"},{"key":"3789_CR8","doi-asserted-by":"publisher","unstructured":"Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, Delfos NM, Leyten EMS, Koster T, Ablij HC, Willem Van't Wout JJ, van Dissel JT: Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection. J Infect. 2018;77(1):18\u201324. \n                    https:\/\/doi.org\/10.1016\/j.jinf.2018.05.007\n                    \n                  . Epub 2018 May 26","DOI":"10.1016\/j.jinf.2018.05.007"},{"key":"3789_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2334-9-131","volume":"9","author":"C Nieuwkoop van","year":"2009","unstructured":"van Nieuwkoop C, van't Wout JW, Assendelft WJ, Elzevier HW, Leyten EM, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Kuijper EJ, et al. Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days). BMC Infect Dis. 2009;9:131.","journal-title":"BMC Infect Dis"},{"key":"3789_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12916-015-0347-y","volume":"13","author":"D Drozdov","year":"2015","unstructured":"Drozdov D, Schwarz S, Kutz A, Grolimund E, Rast AC, Steiner D, Regez K, Schild U, Guglielmetti M, Conca A, et al. Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Med. 2015;13:104.","journal-title":"BMC Med"},{"issue":"9409","key":"3789_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0140-6736(04)15591-8","volume":"363","author":"M Christ-Crain","year":"2004","unstructured":"Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600\u20137.","journal-title":"Lancet"},{"issue":"6","key":"3789_CR12","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/cc9328","volume":"14","author":"C Nieuwkoop van","year":"2010","unstructured":"van Nieuwkoop C, Bonten TN, van't Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care. 2010;14(6):R206.","journal-title":"Crit Care"},{"issue":"7","key":"3789_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ajem.2013.04.012","volume":"31","author":"JH Park","year":"2013","unstructured":"Park JH, Wee JH, Choi SP, Park KN. Serum procalcitonin level for the prediction of severity in women with acute pyelonephritis in the ED: value of procalcitonin in acute pyelonephritis. Am J Emerg Med. 2013;31(7):1092\u20137.","journal-title":"Am J Emerg Med"},{"issue":"5","key":"3789_CR14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/00365513.2013.803231","volume":"73","author":"YE Ha","year":"2013","unstructured":"Ha YE, Kang CI, Wi YM, Chung DR, Kang ES, Lee NY, Song JH, Peck KR. Diagnostic usefulness of procalcitonin as a marker of bacteremia in patients with acute pyelonephritis. Scand J Clin Lab Invest. 2013;73(5):444\u20138.","journal-title":"Scand J Clin Lab Invest"},{"key":"3789_CR15","first-page":"CD007498","volume":"10","author":"P Schuetz","year":"2017","unstructured":"Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10:CD007498.","journal-title":"Cochrane Database Syst Rev"},{"key":"3789_CR16","doi-asserted-by":"crossref","unstructured":"Rhee C. Using Procalcitonin to guide antibiotic therapy. Open forum infectious diseases. 2017, 4(1):ofw249.","DOI":"10.1093\/ofid\/ofw249"},{"issue":"7","key":"3789_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","volume":"16","author":"E Jong de","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819\u201327.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"3789_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/2013.jamainternmed.829","volume":"173","author":"DM Drekonja","year":"2013","unstructured":"Drekonja DM, Rector TS, Cutting A, Johnson JR. Urinary tract infection in male veterans: treatment patterns and outcomes. JAMA Intern Med. 2013;173(1):62\u20138.","journal-title":"JAMA Intern Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3789-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3789-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3789-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T19:08:21Z","timestamp":1581620901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3789-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,14]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3789"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3789-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,14]]},"assertion":[{"value":"25 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was primarily approved by the Medical Ethics Committee of the Leiden University Medical Center (protocol P08.65) and subsequently by all scientific boards of all participating centers. All patients have given written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Darius Wilson is employed by Thermo Fisher Scientific \/ Brahms, Hennigsdorf, Germany. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"161"}}